GANX
Gain Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.25
−0.79%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.26
From 52W high−70.10%
Volume506499.00
Market cap$54.55M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.26
From 52W high
−70.10%
Volume
506499.00
Market cap
$54.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.2x
P/E (TTM)
—
RSI (14)
22.1
MomentumView details →
1D Return
−0.79%
YTD Return
−60.87%
SummaryUpdated Jun 1, 2026
Gain Therapeutics, Inc. (NASDAQ:GANX) is a clinical-stage biotechnology company founded in 2017 and headquartered in Bethesda, Maryland. The company went public in March 2021 and focuses on developing novel therapies for rare genetic diseases and neurological disorders caused by protein misfolding. Gain Therapeutics utilizes its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to discover and develop small molecule treatments that can restore proper protein function in patients with devastating genetic conditions.
Similar companies
Latest newsMore news →
Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing stable MDS-UPDRS motor scores and no disease progression in 12 evaluable participants who completed 12 months of daily oral administration by August 31, 2026.18d agoGain Therapeutics, Inc. Senior Vice President of Finance and principal financial and accounting officer Gianluca Fuggetta resigned effective September 30, 2026.21d ago